Hi Sav,
I have seen well respected, well run, large multi-national companies with a list of collaborators that make SLA's look average pump hundreds of millions of dollars into drugs only to see them fail in phase III trials. So, in short, yes, I could see them putting all that work into something that in the end fails.
Answer me this question, what benefit does holding back the results actually give SLA? What can their competitors learn from the information?
Cheers,
Bill
- Forums
- ASX - By Stock
- SLA
- welcome back solagran
welcome back solagran, page-17
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online